Loading...

PE anti-mouse CD3ε Antibody PE anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
1_145-2c11
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE and CD19 FITC.
  • 1_145-2c11
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE and CD19 FITC.
  • 2_145-2C11_PE_CD3e_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE (filled histogram) or Armenian hamster IgG PE isotype control (open histogram).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100307 50 µg DKK262
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100308 200 µg DKK678
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  4. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  7. Sierro F, et al. 2017. Immunity. 47:374. PubMed
  8. Wang L, et al. 2022. ACS Pharmacol Transl Sci. 5:110. PubMed
  9. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  10. Ocaña-Guzman R, et al. 2022. Cells. 11: . PubMed
  11. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  12. Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed
  13. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  14. Ramdas B, et al. 2022. Mol Ther. 30:2505. PubMed
  15. Zong P, et al. 2022. Nat Cardiovasc Res. 1:344. PubMed
  16. Elazar A, et al. 2022. Elife. 11:. PubMed
  17. Olofsen PA, et al. 2022. Cells. 11:. PubMed
  18. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  19. Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed
  20. Touré H, et al. 2023. PLoS Pathog. 19:e1011257. PubMed
  21. He Y, et al. 2023. Biomolecules. 13:. PubMed
  22. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  23. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  24. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
  25. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  26. Grødeland G, et al. 2020. Front Immunol. 11:431. PubMed
  27. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  28. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  29. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
  30. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
  31. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  32. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  33. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  34. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  35. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  36. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  37. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
  38. Motozono C, et al. 2014. Microbes Infect. 16:320. PubMed
  39. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  40. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  41. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  42. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  43. Vazquez S, et al. 2015. Exp Hematol. 43: 578-585. PubMed
  44. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  45. Vitoriano-Souza J, et al. 2012. PLoS One. 7:e40745. PubMed
  46. Zhang B, et al. 2022. J Exp Med. 219:. PubMed
  47. Yoshida K, et al. 2022. Sci Rep. 12:17276. PubMed
  48. Zhang B, et al. 2016. Mol Cell. 63: 976-89. PubMed
  49. He L, et al. 2019. iScience. 0.790972222. PubMed
  50. Kotaki R, et al. 2020. Sci Rep. 10:13554. PubMed
  51. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  52. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  53. Gaudreault N, et al. 2013. Am J Pathol. 2:605. PubMed
  54. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  55. Ma J, et al. 2016. Proc Natl Acad Sci U S A. 113: 450 - 458. PubMed
  56. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  57. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  58. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  59. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  60. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  61. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  62. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  63. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  64. Abe M, et al. 2020. Clin Exp Immunol. 303:199. PubMed
  65. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  66. Boulay A, et al. 2015. J Neurosci. 35:4427. PubMed
  67. Park HB, et al. 2020. Nat Microbiol. 1319:5. PubMed
  68. Kim P, et al. 2015. Infect Immun . 83: 2992 - 3002. PubMed
  69. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  70. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  71. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
  72. Guo Y, et al. 2013. Infect Immun . 81:3923. PubMed
  73. Abdelfattah N, et al. 2022. Nat Commun. 13:767. PubMed
  74. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  75. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  76. Ha TC, et al. 2020. Hum Gene Ther. 32:458. PubMed
  77. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  78. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  79. Cecchinato V, et al. 2017. J Immunol. 198(1):184-195. PubMed
  80. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  81. Kristensen LK, et al. 2020. Mol Imaging Biol. 1.625694444. PubMed
  82. Martin R, et al. 2014. PLoS One. 9:110609. PubMed
  83. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  84. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  85. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  86. Ji XJ, et al. 2019. Mediators Inflamm. 2019:2750528. PubMed
  87. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  88. Kuo P, et al. 2016. J Am Heart Assoc. 5: 002610. PubMed
  89. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  90. Hara T, et al. 2021. Cancer Cell. 39(6):779-792.e11. PubMed
  91. Hu KH, et al. 2020. Nat Methods. 1.286805556. PubMed
  92. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  93. Celià-Terrassa T, et al. 2017. Nat Cell Biol. 19:711. PubMed
  94. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  95. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  96. Evavold CL, et al. 2021. Cell. 184(17):4495-4511.e19. PubMed
  97. Dyer DP et al. 2019. Immunity. 50(2):378-389 . PubMed
  98. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  99. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  100. Artinger M, et al. 2021. Int J Mol Sci. 22: . PubMed
  101. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  102. Kim I et al. 2015. Brain and behavior. 5(12):e00403 . PubMed
  103. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  104. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  105. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  106. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  107. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  108. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  109. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  110. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  111. Sierro F, et al. 2017. Immunity. 47:374. PubMed
  112. Wang L, et al. 2022. ACS Pharmacol Transl Sci. 5:110. PubMed
  113. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  114. Ocaña-Guzman R, et al. 2022. Cells. 11: . PubMed
  115. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  116. Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed
  117. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  118. Ramdas B, et al. 2022. Mol Ther. 30:2505. PubMed
  119. Zong P, et al. 2022. Nat Cardiovasc Res. 1:344. PubMed
  120. Elazar A, et al. 2022. Elife. 11:. PubMed
  121. Olofsen PA, et al. 2022. Cells. 11:. PubMed
  122. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  123. Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed
  124. Touré H, et al. 2023. PLoS Pathog. 19:e1011257. PubMed
  125. He Y, et al. 2023. Biomolecules. 13:. PubMed
  126. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  127. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  128. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
  129. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  130. Grødeland G, et al. 2020. Front Immunol. 11:431. PubMed
  131. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  132. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  133. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
  134. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
  135. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  136. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  137. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  138. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  139. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  140. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  141. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
  142. Motozono C, et al. 2014. Microbes Infect. 16:320. PubMed
  143. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  144. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  145. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  146. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  147. Vazquez S, et al. 2015. Exp Hematol. 43: 578-585. PubMed
  148. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  149. Vitoriano-Souza J, et al. 2012. PLoS One. 7:e40745. PubMed
  150. Zhang B, et al. 2022. J Exp Med. 219:. PubMed
  151. Yoshida K, et al. 2022. Sci Rep. 12:17276. PubMed
  152. Zhang B, et al. 2016. Mol Cell. 63: 976-89. PubMed
  153. He L, et al. 2019. iScience. 0.790972222. PubMed
  154. Kotaki R, et al. 2020. Sci Rep. 10:13554. PubMed
  155. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  156. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  157. Gaudreault N, et al. 2013. Am J Pathol. 2:605. PubMed
  158. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  159. Ma J, et al. 2016. Proc Natl Acad Sci U S A. 113: 450 - 458. PubMed
  160. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  161. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  162. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  163. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  164. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  165. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  166. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  167. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  168. Abe M, et al. 2020. Clin Exp Immunol. 303:199. PubMed
  169. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  170. Boulay A, et al. 2015. J Neurosci. 35:4427. PubMed
  171. Park HB, et al. 2020. Nat Microbiol. 1319:5. PubMed
  172. Kim P, et al. 2015. Infect Immun . 83: 2992 - 3002. PubMed
  173. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  174. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  175. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
  176. Guo Y, et al. 2013. Infect Immun . 81:3923. PubMed
  177. Abdelfattah N, et al. 2022. Nat Commun. 13:767. PubMed
  178. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  179. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  180. Ha TC, et al. 2020. Hum Gene Ther. 32:458. PubMed
  181. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  182. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  183. Cecchinato V, et al. 2017. J Immunol. 198(1):184-195. PubMed
  184. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  185. Kristensen LK, et al. 2020. Mol Imaging Biol. 1.625694444. PubMed
  186. Martin R, et al. 2014. PLoS One. 9:110609. PubMed
  187. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  188. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  189. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  190. Ji XJ, et al. 2019. Mediators Inflamm. 2019:2750528. PubMed
  191. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  192. Kuo P, et al. 2016. J Am Heart Assoc. 5: 002610. PubMed
  193. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  194. Hara T, et al. 2021. Cancer Cell. 39(6):779-792.e11. PubMed
  195. Hu KH, et al. 2020. Nat Methods. 1.286805556. PubMed
  196. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  197. Celià-Terrassa T, et al. 2017. Nat Cell Biol. 19:711. PubMed
  198. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  199. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  200. Evavold CL, et al. 2021. Cell. 184(17):4495-4511.e19. PubMed
  201. Dyer DP et al. 2019. Immunity. 50(2):378-389 . PubMed
  202. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  203. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  204. Artinger M, et al. 2021. Int J Mol Sci. 22: . PubMed
  205. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  206. Kim I et al. 2015. Brain and behavior. 5(12):e00403 . PubMed
  207. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  208. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
RRID
AB_312672 (BioLegend Cat. No. 100307)
AB_312673 (BioLegend Cat. No. 100308)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD3ε Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε (Maxpar® Ready) 145-2C11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 510™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 605™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 711™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 785™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 750 anti-mouse CD3ε 145-2C11 FC
GoInVivo™ Purified anti-mouse CD3ε 145-2C11 FC
APC anti-mouse CD3ε 145-2C11 FC
Biotin anti-mouse CD3ε 145-2C11 FC,IHC-F
FITC anti-mouse CD3ε 145-2C11 FC
PE anti-mouse CD3ε 145-2C11 FC
PE/Cyanine5 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Alexa Fluor® 488 anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 647 anti-mouse CD3ε 145-2C11 FC,IHC-F,3D IHC
PerCP anti-mouse CD3ε 145-2C11 FC
PerCP/Cyanine5.5 anti-mouse CD3ε 145-2C11 FC
APC/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Pacific Blue™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 421™ anti-mouse CD3ε 145-2C11 FC,ICC
Ultra-LEAF™ Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Spark YG™ 593 anti-mouse CD3 145-2C11 FC
PerCP/Fire™ 780 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 650™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 750™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 810 anti-mouse CD3ε Antibody 145-2C11 FC
Spark YG™ 581 anti-mouse CD3ε (Flexi-Fluor™) 145-2C11 FC
Spark NIR™ 685 anti-mouse CD3ε (Flexi-Fluor™) Antibody 145-2C11 FC
PE/Fire™ 640 anti-mouse CD3ε 145-2C11
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
1_145-2c11
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE and CD19 FITC.
  • 1_145-2c11
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE and CD19 FITC.
  • 2_145-2C11_PE_CD3e_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE (filled histogram) or Armenian hamster IgG PE isotype control (open histogram).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100307 50 µg DKK262
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100308 200 µg DKK678
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  4. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  7. Sierro F, et al. 2017. Immunity. 47:374. PubMed
  8. Wang L, et al. 2022. ACS Pharmacol Transl Sci. 5:110. PubMed
  9. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  10. Ocaña-Guzman R, et al. 2022. Cells. 11: . PubMed
  11. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  12. Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed
  13. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  14. Ramdas B, et al. 2022. Mol Ther. 30:2505. PubMed
  15. Zong P, et al. 2022. Nat Cardiovasc Res. 1:344. PubMed
  16. Elazar A, et al. 2022. Elife. 11:. PubMed
  17. Olofsen PA, et al. 2022. Cells. 11:. PubMed
  18. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  19. Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed
  20. Touré H, et al. 2023. PLoS Pathog. 19:e1011257. PubMed
  21. He Y, et al. 2023. Biomolecules. 13:. PubMed
  22. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  23. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  24. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
  25. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  26. Grødeland G, et al. 2020. Front Immunol. 11:431. PubMed
  27. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  28. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  29. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
  30. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
  31. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  32. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  33. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  34. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  35. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  36. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  37. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
  38. Motozono C, et al. 2014. Microbes Infect. 16:320. PubMed
  39. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  40. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  41. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  42. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  43. Vazquez S, et al. 2015. Exp Hematol. 43: 578-585. PubMed
  44. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  45. Vitoriano-Souza J, et al. 2012. PLoS One. 7:e40745. PubMed
  46. Zhang B, et al. 2022. J Exp Med. 219:. PubMed
  47. Yoshida K, et al. 2022. Sci Rep. 12:17276. PubMed
  48. Zhang B, et al. 2016. Mol Cell. 63: 976-89. PubMed
  49. He L, et al. 2019. iScience. 0.790972222. PubMed
  50. Kotaki R, et al. 2020. Sci Rep. 10:13554. PubMed
  51. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  52. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  53. Gaudreault N, et al. 2013. Am J Pathol. 2:605. PubMed
  54. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  55. Ma J, et al. 2016. Proc Natl Acad Sci U S A. 113: 450 - 458. PubMed
  56. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  57. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  58. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  59. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  60. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  61. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  62. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  63. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  64. Abe M, et al. 2020. Clin Exp Immunol. 303:199. PubMed
  65. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  66. Boulay A, et al. 2015. J Neurosci. 35:4427. PubMed
  67. Park HB, et al. 2020. Nat Microbiol. 1319:5. PubMed
  68. Kim P, et al. 2015. Infect Immun . 83: 2992 - 3002. PubMed
  69. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  70. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  71. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
  72. Guo Y, et al. 2013. Infect Immun . 81:3923. PubMed
  73. Abdelfattah N, et al. 2022. Nat Commun. 13:767. PubMed
  74. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  75. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  76. Ha TC, et al. 2020. Hum Gene Ther. 32:458. PubMed
  77. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  78. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  79. Cecchinato V, et al. 2017. J Immunol. 198(1):184-195. PubMed
  80. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  81. Kristensen LK, et al. 2020. Mol Imaging Biol. 1.625694444. PubMed
  82. Martin R, et al. 2014. PLoS One. 9:110609. PubMed
  83. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  84. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  85. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  86. Ji XJ, et al. 2019. Mediators Inflamm. 2019:2750528. PubMed
  87. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  88. Kuo P, et al. 2016. J Am Heart Assoc. 5: 002610. PubMed
  89. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  90. Hara T, et al. 2021. Cancer Cell. 39(6):779-792.e11. PubMed
  91. Hu KH, et al. 2020. Nat Methods. 1.286805556. PubMed
  92. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  93. Celià-Terrassa T, et al. 2017. Nat Cell Biol. 19:711. PubMed
  94. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  95. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  96. Evavold CL, et al. 2021. Cell. 184(17):4495-4511.e19. PubMed
  97. Dyer DP et al. 2019. Immunity. 50(2):378-389 . PubMed
  98. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  99. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  100. Artinger M, et al. 2021. Int J Mol Sci. 22: . PubMed
  101. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  102. Kim I et al. 2015. Brain and behavior. 5(12):e00403 . PubMed
  103. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  104. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  105. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  106. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  107. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  108. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  109. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  110. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  111. Sierro F, et al. 2017. Immunity. 47:374. PubMed
  112. Wang L, et al. 2022. ACS Pharmacol Transl Sci. 5:110. PubMed
  113. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  114. Ocaña-Guzman R, et al. 2022. Cells. 11: . PubMed
  115. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  116. Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed
  117. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  118. Ramdas B, et al. 2022. Mol Ther. 30:2505. PubMed
  119. Zong P, et al. 2022. Nat Cardiovasc Res. 1:344. PubMed
  120. Elazar A, et al. 2022. Elife. 11:. PubMed
  121. Olofsen PA, et al. 2022. Cells. 11:. PubMed
  122. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  123. Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed
  124. Touré H, et al. 2023. PLoS Pathog. 19:e1011257. PubMed
  125. He Y, et al. 2023. Biomolecules. 13:. PubMed
  126. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  127. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  128. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
  129. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  130. Grødeland G, et al. 2020. Front Immunol. 11:431. PubMed
  131. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  132. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  133. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
  134. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
  135. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  136. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  137. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  138. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  139. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  140. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  141. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
  142. Motozono C, et al. 2014. Microbes Infect. 16:320. PubMed
  143. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  144. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  145. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  146. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  147. Vazquez S, et al. 2015. Exp Hematol. 43: 578-585. PubMed
  148. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  149. Vitoriano-Souza J, et al. 2012. PLoS One. 7:e40745. PubMed
  150. Zhang B, et al. 2022. J Exp Med. 219:. PubMed
  151. Yoshida K, et al. 2022. Sci Rep. 12:17276. PubMed
  152. Zhang B, et al. 2016. Mol Cell. 63: 976-89. PubMed
  153. He L, et al. 2019. iScience. 0.790972222. PubMed
  154. Kotaki R, et al. 2020. Sci Rep. 10:13554. PubMed
  155. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  156. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  157. Gaudreault N, et al. 2013. Am J Pathol. 2:605. PubMed
  158. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  159. Ma J, et al. 2016. Proc Natl Acad Sci U S A. 113: 450 - 458. PubMed
  160. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  161. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  162. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  163. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  164. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  165. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  166. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  167. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  168. Abe M, et al. 2020. Clin Exp Immunol. 303:199. PubMed
  169. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  170. Boulay A, et al. 2015. J Neurosci. 35:4427. PubMed
  171. Park HB, et al. 2020. Nat Microbiol. 1319:5. PubMed
  172. Kim P, et al. 2015. Infect Immun . 83: 2992 - 3002. PubMed
  173. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  174. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  175. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
  176. Guo Y, et al. 2013. Infect Immun . 81:3923. PubMed
  177. Abdelfattah N, et al. 2022. Nat Commun. 13:767. PubMed
  178. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  179. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  180. Ha TC, et al. 2020. Hum Gene Ther. 32:458. PubMed
  181. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  182. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  183. Cecchinato V, et al. 2017. J Immunol. 198(1):184-195. PubMed
  184. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  185. Kristensen LK, et al. 2020. Mol Imaging Biol. 1.625694444. PubMed
  186. Martin R, et al. 2014. PLoS One. 9:110609. PubMed
  187. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  188. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  189. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  190. Ji XJ, et al. 2019. Mediators Inflamm. 2019:2750528. PubMed
  191. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  192. Kuo P, et al. 2016. J Am Heart Assoc. 5: 002610. PubMed
  193. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  194. Hara T, et al. 2021. Cancer Cell. 39(6):779-792.e11. PubMed
  195. Hu KH, et al. 2020. Nat Methods. 1.286805556. PubMed
  196. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  197. Celià-Terrassa T, et al. 2017. Nat Cell Biol. 19:711. PubMed
  198. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  199. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  200. Evavold CL, et al. 2021. Cell. 184(17):4495-4511.e19. PubMed
  201. Dyer DP et al. 2019. Immunity. 50(2):378-389 . PubMed
  202. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  203. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  204. Artinger M, et al. 2021. Int J Mol Sci. 22: . PubMed
  205. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  206. Kim I et al. 2015. Brain and behavior. 5(12):e00403 . PubMed
  207. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  208. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
RRID
AB_312672 (BioLegend Cat. No. 100307)
AB_312673 (BioLegend Cat. No. 100308)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD3ε Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε (Maxpar® Ready) 145-2C11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 510™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 605™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 711™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 785™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 750 anti-mouse CD3ε 145-2C11 FC
GoInVivo™ Purified anti-mouse CD3ε 145-2C11 FC
APC anti-mouse CD3ε 145-2C11 FC
Biotin anti-mouse CD3ε 145-2C11 FC,IHC-F
FITC anti-mouse CD3ε 145-2C11 FC
PE anti-mouse CD3ε 145-2C11 FC
PE/Cyanine5 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Alexa Fluor® 488 anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 647 anti-mouse CD3ε 145-2C11 FC,IHC-F,3D IHC
PerCP anti-mouse CD3ε 145-2C11 FC
PerCP/Cyanine5.5 anti-mouse CD3ε 145-2C11 FC
APC/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Pacific Blue™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 421™ anti-mouse CD3ε 145-2C11 FC,ICC
Ultra-LEAF™ Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Spark YG™ 593 anti-mouse CD3 145-2C11 FC
PerCP/Fire™ 780 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 650™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 750™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 810 anti-mouse CD3ε Antibody 145-2C11 FC
Spark YG™ 581 anti-mouse CD3ε (Flexi-Fluor™) 145-2C11 FC
Spark NIR™ 685 anti-mouse CD3ε (Flexi-Fluor™) Antibody 145-2C11 FC
PE/Fire™ 640 anti-mouse CD3ε 145-2C11
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account